- Home
- PAM vs TFX Comparison
PAM vs TFX Comparison
Compare PAM & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAM | TFX |
|---|---|---|
| Founded | 1945 | 1943 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PAM | TFX |
|---|---|---|
| Price | $89.19 | $122.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 10 |
| Target Price | $92.75 | ★ $139.88 |
| AVG Volume (30 Days) | 127.9K | ★ 759.0K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $1,926,000,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $136,919.08 | $9.90 |
| Revenue Next Year | $36.38 | $10.51 |
| P/E Ratio | $15.76 | ★ N/A |
| Revenue Growth | N/A | ★ 5.42 |
| 52 Week Low | $54.95 | $102.58 |
| 52 Week High | $97.55 | $185.94 |
Technical Indicators
Market Signals| Indicator | PAM | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 51.77 |
| Support Level | $87.94 | $121.76 |
| Resistance Level | $90.33 | $126.13 |
| Average True Range (ATR) | 2.95 | 3.90 |
| MACD | -0.57 | -0.23 |
| Stochastic Oscillator | 35.97 | 22.54 |
Price Performance
Historical ComparisonAbout PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.